Osteoclast inhibitors such as zoledronic acid for low back pain treatment
View Patent ↗Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as Modic changes type I.
1. A method of treating a Modic change type I, comprising: administering zoledronic acid to a human in need thereof, wherein the human experiences pain relief three months after the zoledronic acid is administered.
2. The method of claim 1 , wherein the zoledronic acid is orally administered.
3. The method of claim 2 , wherein about 50 mg to about 600 mg of the zoledronic acid is orally administered.
4. The method of claim 2 , wherein about 200 mg to about 400 mg of the zoledronic acid is orally administered.
5. The method of claim 2 , wherein about 400 mg to about 500 mg of the zoledronic acid is orally administered.
6. The method of claim 2 , wherein about 150 mg to about 200 mg of the zoledronic acid is orally administered.
7. The method of claim 2 , wherein a dose of about 100 mg to about 200 mg of the zoledronic acid is orally administered 2 or 3 times in a month.
8. The method of claim 2 , wherein about 50 mg to about 60 mg of the zoledronic acid in a disodium salt form is orally administered weekly.
9. The method of claim 8 , wherein the zoledronic acid is administered weekly for 6 weeks.
10. The method of claim 2 , wherein the zoledronic acid is orally administered weekly for one or two months.
11. The method of claim 2 , wherein the zoledronic acid is orally administered weekly for 6 weeks.
12. The method of claim 1 , wherein the Modic change is located at C1/2, C2/3, C3/4, C4/5, C5/6, or C6/7.
13. The method of claim 1 , wherein the Modic change is located at C7/T1, T1/2, T2/3, T3/4, T4/5, T5/6, T6/7, T7/8, T8/9, T9/10, T10/11, or T11/12.
14. The method of claim 1 , wherein the Modic change is located at T12/L1, L1/2, L2/3, L3/4, L4/5, or L5/S1.
15. The method of claim 1 , wherein the human achieves a reduction in the size of the Modic change type I of at least about 5% relative to the baseline before the zoledronic acid is administered.
16. The method of claim 1 , wherein the human has the Modic change type I at two or more levels.
17. The method of claim 1 , wherein the zoledronic acid is orally administered in a manner that results in a 24-hour sustained plasma level factor that is at least about 2 times that of 4 mg of zoledronic acid administered intravenously.
18. The method of claim 1 , wherein the zoledronic acid is orally administered in a manner that results in a 48-hour sustained plasma level factor that is at least twice that of 1 mg of zoledronic acid administered intravenously.
19. The method of claim 1 , wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is at least 1.1%.
20. The method of claim 2 , wherein the zoledronic acid is orally administered in a manner that results in a bioavailability that is 1.3% to 3%.
21. The method of claim 1 , wherein the human experiences pain relief for at least 3 weeks.
22. The method of claim 1 , wherein the human experiences a reduction in pain that lasts at least three months.
23. The method of claim 2 , wherein the human is fasted for at least 2 hours before the zoledronic acid is orally administered.
24. The method of claim 2 , wherein the human is fasted for at least 30 minutes after the zoledronic acid is orally administered.
25. The method of claim 2 , wherein the human is fasted for at least 1 hour after the zoledronic acid is orally administered.
26. The method of claim 2 , wherein the human is fasted for at least 4 hours before the zoledronic acid is orally administered.
27. The method of claim 2 , wherein the human is fasted for at least 8 hours before the zoledronic acid is orally administered.
28. The method of claim 2 , wherein the human remains upright or sits upright for at least 30 minutes after the zoledronic acid is orally administered.
29. The method of claim 2 , wherein the size of the Modic change type I relative to the baseline prior to administration remains reduced for at least about 3 months after the zoledronic acid is orally administered.
30. The method of claim 2 , wherein the size of the Modic change type I relative to the baseline prior to administration is reduced at about 3 months after the zoledronic acid is orally administered.